Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases

Successful application of lorlatinib in a 23‐year‐old patient with anaplastic lymphoma kinase (ALK)‐positive lung cancer and multiple brain metastases

Abstract Background Anaplastic lymphoma kinase (ALK)‐positive lung cancer has a better long‐term prognosis with ALK‐inhibitor than other lung cancers. However, resistance to ALK‐inhibitors and the control of metastases in the central nervous system (CNS) remain to be a challenge in the management of...

Full description

Bibliographic Details
Main Authors: Yosuke Murakami, Yosuke Kawashima, Shinji Chiba, Shuichiro Hara, Yusuke Yamazaki, Tsuyoshi Doman, Shin Saito, Tetsuo Odaka, Takahiro Ogasawara, Hisashi Shimizu, Jun Sugisaka, Tomoiki Aiba, Yukihiro Toi, Shinsuke Yamanda, Yuichiro Kimura, Shunichi Sugawara
Format: Article
Language:English
Published: Wiley 2024-02-01
Series:Cancer Reports
Subjects:
anaplastic lymphoma kinase (ALK)‐positive lung cancer
central nervous system (CNS) metastasis
second‐line treatment
Online Access:https://doi.org/10.1002/cnr2.1981

Internet

https://doi.org/10.1002/cnr2.1981

Similar Items